ReviewNature cardiovascular research2024
Challenges and perspectives of heart repair with pluripotent stem cell-derived cardiomyocytes.
Review in Nature cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Bright Ferritin for Non-Invasive MRI Monitoring of the Fate of Transplanted hPSC-Cardiomyocytes in the Infarcted Rat Heart.Magnetic resonance in medicine · 2026Article
- Phosphatidylserine-everted erythrocyte membrane vesicles enhance efferocytosis and remodeling of vascular grafts.Nature communications · 2026Article
- Vascularized Cardiac Tissue Engineering: From Advances in Biofabrication to Translational Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Past, Present and Future of Regenerative Gene Therapy for Ischemic Heart Failure.Journal of cardiovascular translational research · 2026Review
- Heart Regeneration for Clinical Application.Internal medicine (Tokyo, Japan) · 2026Review
- Safety and Engraftment of Aligned Cardiac Patches Loaded with hiPSC-CMs in a Large Animal Model of Myocardial Infarction.Theranostics · 2026Article
- Volumetric 3D Printing and Melt-Electrowriting to Fabricate Implantable Reinforced Cardiac Tissue Patches.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Pluripotent stem cell-based approaches for heart repair and the potential of genetic modifications.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Cardiac repair and regeneration: cell therapy, in vivo reprogramming, and the promise of extracellular vesicles.Experimental & molecular medicine · 2025Review
- Exploring hiPSC-CM replacement therapy in ischemic hearts.Basic research in cardiology · 2025Review
- Stem Cell and Synthetic Embryo Models: Advances, Applications, and Ethical Considerations.Stem cell reviews and reports · 2025Review
- Sirt4 Deficiency Promotes Cardiomyocyte Proliferation and Cardiac Repair.Journal of cellular and molecular medicine · 2025Article
- Cardiomyocyte regeneration after infarction: changes, opportunities and challenges.Molecular and cellular biochemistry · 2025Review
- Cardiomyocyte regeneration: lessons from neonatal hearts.Regenerative medicine · 2025Article
- Hypoimmunogenic hPSC-derived cardiac organoids for immune evasion and heart repair.bioRxiv : the preprint server for biology · 2025Article
- Modulation of cardiomyocyte contractility and action potentials with chemogenetic chloride currents.The Journal of physiology · 2025Article
- Molecular Regulation of Cardiomyocyte Maturation.Current cardiology reports · 2025Review
- Review
- Protective effects of 7-hydroxyflavone on mitochondrial membrane potential and hydrogen peroxide-induced apoptosis in cardiomyocytes.Tzu chi medical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Here we aim at providing a concise but comprehensive overview of the perspectives and challenges of heart repair with pluripotent stem cell-derived cardiomyocytes. This Review comes at a time when consensus has been reached about the lack of relevant proliferative capacity of adult mammalian cardiomyocytes and the lack of new heart muscle formation with autologous cell sources. While alternatives to cell-based approaches will be shortly summarized, the focus lies on pluripotent stem cell-derived cardiomyocyte repair, which entered first clinical trials just 2 years ago. In the view of the authors, these early trials are important but have to be viewed as early proof-of-concept trials in humans that will hopefully provide first answers on feasibility, safety and the survival of allogeneic pluripotent stem cell-derived cardiomyocyte in the human heart. Better approaches have to be developed to make this approach clinically applicable.
Indexed as
Identifiers
39195938What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.